# US 2013/0251707 A1 · ANTI-huTNFR1 ANTIBODY

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0251707 A1
- Document ID: US20130251707A1
- Status: Published application
- Kind: A1
- Application number: 13/823,008
- Filed: 2011-09-16
- Published: 2013-09-26
- Earliest claimed: 2010-09-16
- Assignees: Baliopharm AG
- Inventors: Roland Kontermann; Klaus Pfizenmaier; Andreas Herrmann; Kirstin Zettlitz
- Web page: https://patentgrep.com/patent/US20130251707A1

## CPC

- C07K 16/2866: {against receptors for cytokines, lymphokines, interferons}
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 17/06: Antipsoriatics
- A61P 19/00: Drugs for skeletal disorders
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/04: Antibacterial agents
- A61P 35/00: Antineoplastic agents
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- C07K 16/2878: {against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/41: Glycosylation, sialylation, or fucosylation
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/71: Decreased effector function due to an Fc-modification
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The disclosure to an anti-huTNFR1 antibody of the IgG1 type, which has a modified Fc region deficient in mediating effector function, a pharmaceutical preparation comprising such antibody, and an anti-huTNFR1 antibody of the IgG1 type for use as a TNF antagonist without forming an agonistic TNFR1 signalling complex, as an alternative to treatment with an anti-TNF therapeutic.

## Claims

### Claim 1

An anti-huTNFR1 antibody of the IgG1 type having a modified Fc region deficient in mediating effector function.

### Claim 2 (depends on 1)

The antibody of claim 1, wherein the Fc region comprises a mutation to downmodulate the effector function.

### Claim 3 (depends on 2)

The antibody of claim 2, wherein the Fc region is glycoengineered to downmodulate the effector function.

### Claim 4 (depends on 1)

The antibody of claim 1, wherein the Fc region comprises a heavy chain with at least one mutation selected from the group consisting of E233P, L234V, L235A, ΔG236, A327G, A330S and P331S.

### Claim 5 (depends on 1)

The antibody of claim 1, wherein the antibody binds specifically to an epitope comprising the membrane-distal CRD1 of huTNFR1 and subdomain A1 of CRD2 of huTNFR1.

### Claim 6 (depends on 1)

The antibody of claim 1, wherein the antibody binds specifically to an epitope represented by amino acids 1 to 70 in the N-terminal region of huTNFR1.

### Claim 7 (depends on 1)

The antibody of claim 1, wherein the antibody binds specifically to the epitope recognized by the H398 antibody.

### Claim 8 (depends on 1)

The antibody of claim 1, wherein the antibody binds specifically to huTNFR1 by at least two binding sites.

### Claim 9 (depends on 1)

The antibody of claim 1, wherein the antibody is a humanized H398 antibody.

### Claim 10 (depends on 1)

A pharmaceutical preparation comprising an antibody according to claim 1 and a pharmaceutically acceptable carrier.

### Claim 11 (depends on 1)

The antibody of claim 1, wherein the antibody is produced by a recombinant mammalian expression system.

### Claim 12 (depends on 11)

The antibody of claim 11, wherein a CHO production cell line is employed to produce the antibody.

### Claim 13

A method of treating a condition associated with expression of TNFR1 comprising the step of administering a therapeutically effective amount of an anti-huTNFR1 antibody of the IgG1 type to a patient in need thereof.

### Claim 14 (depends on 13)

The method of claim 13, wherein the antibody is administered after anti-TNF or a non biologic disease modifying antirheumatic drug (DMARD) therapeutic has been administered to the patient and has not been effective in treating the condition.

### Claim 15 (depends on 13)

The method of claim 13, wherein the condition is selected from the group consisting of an autoimmune disease, congestive heart failure, metabolic disease, cytokine release syndrome, septic shock, a chronic neurodegenerative disease, stroke, and cancer.

### Claim 16 (depends on 15)

The method of claim 15, wherein the autoimmune disease is selected from the group consisting of rheumatoid arthritis, psoriasis, psoriatic arthritis, juvenile arthritis, ankylosing spondylitis, Crohn's disease and multiple sclerosis.

### Claim 17 (depends on 15)

The method of claim 15, wherein the chronic neurodegenerative disease is Alzheimer's disease or Parkinson's disease.
